The present invention relates to a one-way blower or breath-driven nasal device providing a unique dual flow for propelling a pharmaceutical substance into the
nasal cavity, preferably into the upper
nasal cavity and into the olfactory region and the trigeminal mucosa, for rapid
diffusion into the brain for the treatment of nasal and / or
central nervous system ("CNS") injuries, diseases or disorders, and for the treatment of nasal and / or
central nervous system ("CNS") injuries, diseases or disorders. The present invention relates to brain injury, in particular brain injury including
cerebral concussion (e.g.,
traumatic brain injury ("TBI")), and methods related to nasal treatments therewith. Respiratory driven nasal devices are disclosed for delivering a tight or restricted concentrated plume of
drug substance to a targeted site deep in the
nasal cavity, bypassing the
blood brain barrier (i.e., olfactory nerve) to provide concentrated
drug substance for direct absorption by the brain. The restricted plume of the
drug substance ejected from the nasal device by
breathing of the patient is narrow in the vertical direction, similar to the
diameter of the inner chamber in which the drug substance is stored. By creating such a narrow or restricted plume, higher concentrations of drug substances can be deposited at deeper nasal targeting sites. The breath-driven nasal device of the present invention achieves this unique
advantage by using a novel double elongate double-walled tube chamber consisting of an outer hollow chamber and an inner chamber wherein the inner chamber is stabilized in the outer chamber by preferably two, three or more ribs. More specifically, the breath-driven nasal device simultaneously blows air through both chambers at the same force rate using the patient's own breath. When the blown air exits from the two chambers, propulsion air from the outer tube chamber encloses the drug substance propelled from the inner tube chamber in the blown air, forcing the drug substance to exit vertically in a tight or restricted concentrated plume shape, whereby the drug substance can be released from the outer tube chamber as compared to the drug substance exiting a conical fan-out plume shape of a single hollow chamber. And the drug substances with higher concentration reach the targeted nasal part (as shown in Figure 44-45). This unique feature allows the
pharmaceutical substances to more effectively treat brain diseases or injuries without or to minimize systemic or
blood brain barrier ("BBB") issues. According to the invention, air is blown through the two inner drug chambers by utilizing natural
respiration of a patient, so that drug substances are pushed into the deep part of the nasal cavity from the inner drug substance chambers to reach a targeted part and bypass the BBB, and possibility is provided for better treatment of
central nervous system diseases, such as
traumatic brain injury, including
cerebral concussion,
migraine,
epilepsy,
insomnia and
postoperative pain, and the
treatment effect is good. The latter is typically relieved by opioids.